Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial
m-DOT did not increase adherence to HU treatment. We recommend that further testing in larger trials with a longer follow up period be undertaken.
Authors
- Sharon E. Cox (ORCID: https://orcid.org/0000-0002-9908-2936)
- Enrico M. Novelli (ORCID: https://orcid.org/0000-0003-3010-8285)
- Abel Makubi (ORCID: https://orcid.org/0000-0002-0866-6726)
- Bruno P. Mmbando (ORCID: https://orcid.org/0000-0001-7232-8708)
- Philip Sasi (ORCID: https://orcid.org/0000-0002-9911-8302)
- Mariam Ngaeje
- Julie Makani (ORCID: https://orcid.org/0000-0002-4801-6250)
- Raphael Zozimus Sangeda (ORCID: https://orcid.org/0000-0002-6574-5308)
- Joseph Soka
- Caterina Rosano (ORCID: https://orcid.org/0000-0002-0909-1506)
- Alex Magesa
Institutions
- Muhimbili University of Health and Allied Sciences (TZ)
- University of Pittsburgh (US)
- London School of Hygiene & Tropical Medicine (GB)
- The Coordinating Center (US)
- Ministry of Health, Community Development, Gender, Elderly and Children (TZ)
- Muhimbili National Hospital (TZ)
- National Institute for Medical Research (TZ)
- Nagasaki University (JP)
- Imperial College London (GB)
Publication Details
- Journal
- Communications Medicine
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1038/s43856-024-00552-5
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Pittsburgh
- Muhimbili University of Health and Allied Sciences
- University of Health and Allied Sciences
- Vascular Medicine Institute, University of Pittsburgh